London, 15 October 2014: TechNavio, the independent tech-focused global research firm, has published a report on the Global Peptide Therapeutics Market 2014-2018, which is expected to grow at a CAGR of 9.25 percent during the period 2013-2018.
Peptides are organic compounds that are composed of amino acids linked together chemically by peptide bonds. They are among the most potent biologically active substances found in nature, and are used to control, trigger, and maintain physiological processes in living beings. However, the use of peptides as therapeutic agents has always been difficult because of their inherent instability and incapability of passing through cellular membranes. Peptides also entail the requirement of specific technology to tackle the extensive and challenging steps in their synthesis.
“Potent peptide therapeutics has a better ability to act on the target, which increases the efficacy of the treatment,” says Faisal Ghaus, Vice President of TechNavio.
“Peptides are becoming increasingly popular because of their higher efficacy profile and a better understanding of structural biology, pharmacodynamics, and pharmacokinetics.”
Key Market Drivers
- Increase in Patient Population
- Advances in Technology for Peptide Synthesis
- Unmet Medical Need
- Increase in Healthcare Spending
Key Market Trends
- Growing Popularity
- Contract Manufacturing
- High Market Competition
Key Market Vendors
- AstraZeneca plc
- Eli Lilly and Co.
- Novo Nordisk A/S
- Sanofi
To define the market circumstances in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
